Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrrolitinib in HER-2+ Early/Locally Advanced Breast Cancer After Trastuzumab
NCT06470347Phase 2Recruiting
- Sponsor
- Zunyi Medical University
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Zunyi Medical University. Started Nov 2022; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06470347.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470347.